This post was originally published on this site
The therapy , Adstiladrin, was approved for adult patients. It has be to administered once every three months into the patient’s bladder via a urinary catheter.
Ferring did not respond to a Reuters request for comment.
The safety and effectiveness of Adstiladrin was evaluated in a multi-center clinical study that included 157 patients, FDA said.
